Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products candidates for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. The company develops PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 negative allosteric modulator (NAM) for chronic spontaneous urticaria and other mast cell diseases; and TSHR Program, an oral small molecule TSHR NAM for graves' disease and thyroid eye disease. It also develops oral small molecule single- and multi-incretin receptor agonists for metabolic disorders including obesity and type 2 diabetes. In addition, the company focuses on other therapeutic areas, including neurology, women's health, cardiovascular disease, and respiratory disease. Septerna, Inc. was formerly known as GPCR NewCo, Inc. and changed its name to Septerna Inc. in June 2021. The company was incorporated in 2019 and is headquartered in South San Francisco, California.

Septerna Inc.

Septerna, Inc. ( ($SEPN) ) has issued an announcement. At its annual meeting of stockholders held on June 26, 2026, Septerna, Inc. reported that sh...

Septerna Shareholders Elect Directors, Ratify Ernst & Young

In a report released yesterday, Joshua Schimmer from Cantor Fitzgerald maintained a Buy rating on Septerna, Inc., with a price target of $60.00. Th...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	SEPN	$34.54	+0.52%	650.78K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	SEPN	$34.54	+0.5%	650.78K
3
4
5
6

SEPN

SEPN

Get Septerna Inc. Data in Excel

Get Septerna Inc. Data in Excel